Piperacillin–tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN)
Antimicrobial Stewardship & Healthcare Epidemiology · 2026 · 6 (1)
DOI: 10.1017/ash.2026.10322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 27.03.2026. Verfasst von Avneet Purewal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fraser Health Authority, Canada. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Piperacillin–tazobactam is a beta-lactam antibiotic with a distinct R1 side chain compared to other penicillins, therefore the risk of cross-reactivity should be theoretically low. Despite this difference, antimicrobial guidelines recommend against using piperacillin–tazobactam in patients with penicillin allergies. There is limited data available regarding piperacillin–tazobactam use in patients with a penicillin allergy, or rates of cross-reactivity. Therefore, the objective of this study was to assess the incidence of cross-reactivity to piperacillin–tazobactam in patients with a labeled penicillin allergy.
Methods
This was a retrospective study of patients admitted to Surrey Memorial Hospital (SMH) between November 1 st , 2021 to January 31 st , 2024 assessing tolerance to piperacillin–tazobactam in patients with prior labeled penicillin allergies. Baseline characteristics and outcomes were collected from electronic medical records (EMR).
Results
Of the 191 patients included, 98% were found to tolerate one or more doses of piperacillin–tazobactam. This included 95 patients with “low risk delayed reactions,” 90 patients with “high risk anaphylactic reactions,” and 2 patients with “well-documented delayed reactions,” to penicillins. Only four patients out of 191 had documented intolerance to piperacillin-tazobactam post-exposure.
Conclusion
This study suggests that piperacillin–tazobactam has a low risk of intolerability (2%) in patients with labeled penicillin allergies, and that it is reasonable to consider piperacillin–tazobactam as an alternative to carbapenems and other broad-spectrum antibiotics for most patients with a previous penicillin allergy.
Autor:innen und Institutionen
- Fraser Health Authority, Canada.
- The University of British Columbia, Canada.
ORCID-Profile: Avneet Purewal, Kieran Shah, Sarah N Stabler, Kevin Afra, Ke Su
Zitieren
APA
Purewal, A., Shah, K., Stabler, S. N., Afra, K., & Su, K. (2026). Piperacillin–tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN). Antimicrobial Stewardship & Healthcare Epidemiology, 6(1). https://doi.org/10.1017/ash.2026.10322
Vancouver
Purewal A, Shah K, Stabler SN, Afra K, Su K. Piperacillin–tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN). Antimicrobial Stewardship & Healthcare Epidemiology. 2026;6(1). doi:10.1017/ash.2026.10322
BibTeX
@article{Purewal2026,
author = {Purewal, Avneet and Shah, Kieran and Stabler, Sarah N and Afra, Kevin and Su, Ke},
title = {Piperacillin–tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN)},
journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1017/ash.2026.10322}
}
EUVIMED